RESUMO
Background Access to supplemental screening breast MRI is determined using traditional risk models, which are limited by modest predictive accuracy. Purpose To compare the diagnostic accuracy of a mammogram-based deep learning (DL) risk assessment model to that of traditional breast cancer risk models in patients who underwent supplemental screening with MRI. Materials and Methods This retrospective study included consecutive patients undergoing breast cancer screening MRI from September 2017 to September 2020 at four facilities. Risk was assessed using the Tyrer-Cuzick (TC) and National Cancer Institute Breast Cancer Risk Assessment Tool (BCRAT) 5-year and lifetime models as well as a DL 5-year model that generated a risk score based on the most recent screening mammogram. A risk score of 1.67% or higher defined increased risk for traditional 5-year models, a risk score of 20% or higher defined high risk for traditional lifetime models, and absolute scores of 2.3 or higher and 6.6 or higher defined increased and high risk, respectively, for the DL model. Model accuracy metrics including cancer detection rate (CDR) and positive predictive values (PPVs) (PPV of abnormal findings at screening [PPV1], PPV of biopsies recommended [PPV2], and PPV of biopsies performed [PPV3]) were compared using logistic regression models. Results This study included 2168 women who underwent 4247 high-risk screening MRI examinations (median age, 54 years [IQR, 48-60 years]). CDR (per 1000 examinations) was higher in patients at high risk according to the DL model (20.6 [95% CI: 11.8, 35.6]) than according to the TC (6.0 [95% CI: 2.9, 12.3]; P < .01) and BCRAT (6.8 [95% CI: 2.9, 15.8]; P = .04) lifetime models. PPV1, PPV2, and PPV3 were higher in patients identified as high risk by the DL model (PPV1, 14.6%; PPV2, 32.4%; PPV3, 36.4%) than those identified as high risk with the TC (PPV1, 5.0%; PPV2, 12.7%; PPV3, 13.5%; P value range, .02-.03) and BCRAT (PPV1, 5.5%; PPV2, 11.1%; PPV3, 12.5%; P value range, .02-.05) lifetime models. Conclusion Patients identified as high risk by a mammogram-based DL risk assessment model showed higher CDR at breast screening MRI than patients identified as high risk with traditional risk models. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Bae in this issue.
Assuntos
Neoplasias da Mama , Aprendizado Profundo , Humanos , Feminino , Pessoa de Meia-Idade , Detecção Precoce de Câncer , Neoplasias da Mama/diagnóstico por imagem , Estudos Retrospectivos , Imageamento por Ressonância MagnéticaRESUMO
OBJECTIVE: To investigate the impact of thoracic body composition on outcomes after lobectomy for lung cancer. SUMMARY AND BACKGROUND DATA: Preoperative identification of patients at risk for adverse outcomes permits treatment modification. The impact of body composition on lung resection outcomes has not been investigated in a multicenter setting. METHODS: A total of 958 consecutive patients undergoing lobectomy for lung cancer at 3 centers from 2014 to 2017 were retrospectively analyzed. Muscle and adipose tissue cross-sectional area at the fifth, eighth, and tenth thoracic vertebral body was quantified. Prospectively collected outcomes from a national database were abstracted to characterize the association between sums of muscle and adipose tissue and hospital length of stay (LOS), number of any postoperative complications, and number of respiratory postoperative complications using multivariate regression. A priori determined covariates were forced expiratory volume in 1 second and diffusion capacity of the lungs for carbon monoxide predicted, age, sex, body mass index, race, surgical approach, smoking status, Zubrod and American Society of Anesthesiologists scores. RESULTS: Mean patient age was 67âyears, body mass index 27.4âkg/m2 and 65% had stage i disease. Sixty-three percent underwent minimally invasive lobectomy. Median LOS was 4âdays and 34% of patients experienced complications. Muscle (using 30âcm2 increments) was an independent predictor of LOS (adjusted coefficient 0.972; P = 0.002), any postoperative complications (odds ratio 0.897; P = 0.007) and postoperative respiratory complications (odds ratio 0.860; P = 0.010). Sarcopenic obesity was also associated with LOS and adverse outcomes. CONCLUSIONS: Body composition on preoperative chest computed tomography is an independent predictor of LOS and postoperative complications after lobectomy for lung cancer.
Assuntos
Neoplasias Pulmonares , Pneumonectomia , Idoso , Composição Corporal , Hospitais , Humanos , Tempo de Internação , Neoplasias Pulmonares/cirurgia , Pneumonectomia/efeitos adversos , Pneumonectomia/métodos , Complicações Pós-Operatórias/etiologia , Estudos Retrospectivos , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND. Screening mammography facilities closed during the COVID-19 pandemic in spring 2020. Recovery of screening volumes has varied across patient subgroups and facilities. OBJECTIVE. We compared screening mammography volumes and patient and facility characteristics between periods before COVID-19 and early and later postclosure recovery periods. METHODS. This retrospective study included screening mammograms performed in the same 2-month period (May 26-July 26) in 2019 (pre-COVID-19), 2020 (early recovery), and 2021 (late recovery after targeted interventions to expand access) and across multiple facility types (urban, suburban, community health center). Suburban sites had highest proportion of White patients and the greatest scheduling flexibility and expanded appointments during initial reopening. Findings were compared across years. RESULTS. For White patients, volumes decreased 36.6% from 6550 in 2019 (4384 in 2020) and then increased 61.0% to 6579 in 2021; for patients with races other than White, volumes decreased 53.9% from 1321 in 2019 (609 in 2020) and then increased 136.8% to 1442 in 2021. The percentage of mammograms in patients with races other than White was 16.8% in 2019, 12.2% in 2020, and 18.0% in 2021. The proportion performed at the urban center was 55.3% in 2019, 42.2% in 2020, and 45.9% in 2021; the proportion at suburban sites was 34.0% in 2019, 49.2% in 2020, and 43.5% in 2021. Pre-COVID-19 volumes were reached by the sixth week after reopening for suburban sites but were not reached during early recovery for the other sites. The proportion that were performed on Saturday for suburban sites was similar across periods, whereas the proportion performed on Saturday for the urban site was 7.6% in 2019, 5.3% in 2020, and 8.8% in 2021; the community health center did not offer Saturday appointments during recovery. CONCLUSION. After reopening, screening shifted from urban to suburban settings, with a disproportionate screening decrease in patients with races other than White. Initial delayed access at facilities serving underserved populations exacerbated disparities. Interventions to expand access resulted in late recovery volumes exceeding prepandemic volumes in patients with races other than White. CLINICAL IMPACT. Interventions to support equitable access across facilities serving diverse patient populations may mitigate potential widening disparities in breast cancer diagnosis during the pandemic.
Assuntos
Neoplasias da Mama , COVID-19 , Acessibilidade Arquitetônica , Neoplasias da Mama/diagnóstico por imagem , Detecção Precoce de Câncer , Feminino , Humanos , Mamografia/métodos , Programas de Rastreamento , Pandemias , Estudos RetrospectivosRESUMO
BACKGROUND. The need for second visits between screening mammography and diagnostic imaging contributes to disparities in the time to breast cancer diagnosis. During the COVID-19 pandemic, an immediate-read screening mammography program was implemented to reduce patient visits and decrease time to diagnostic imaging. OBJECTIVE. The purpose of this study was to measure the impact of an immediate-read screening program with focus on disparities in same-day diagnostic imaging after abnormal findings are made at screening mammography. METHODS. In May 2020, an immediate-read screening program was implemented whereby a dedicated breast imaging radiologist interpreted all screening mammograms in real time; patients received results before discharge; and efforts were made to perform any recommended diagnostic imaging during the visit (performed by different radiologists). Screening mammographic examinations performed from June 1, 2019, through October 31, 2019 (preimplementation period), and from June 1, 2020, through October 31, 2020 (postimplementation period), were retrospectively identified. Patient characteristics were recorded from the electronic medical record. Multivariable logistic regression models incorporating patient age, race and ethnicity, language, and insurance type were estimated to identify factors associated with same-day diagnostic imaging. Screening metrics were compared between periods. RESULTS. A total of 8222 preimplementation and 7235 postimplementation screening examinations were included; 521 patients had abnormal screening findings before implementation, and 359 after implementation. Before implementation, 14.8% of patients underwent same-day diagnostic imaging after abnormal screening mammograms. This percentage increased to 60.7% after implementation. Before implementation, patients who identified their race as other than White had significantly lower odds than patients who identified their race as White of undergoing same-day diagnostic imaging after receiving abnormal screening results (adjusted odds ratio, 0.30; 95% CI, 0.10-0.86; p = .03). After implementation, the odds of same-day diagnostic imaging were not significantly different between patients of other races and White patients (adjusted odds ratio, 0.92; 95% CI, 0.50-1.71; p = .80). After implementation, there was no significant difference in race and ethnicity between patients who underwent and those who did not undergo same-day diagnostic imaging after receiving abnormal results of screening mammography (p > .05). The rate of abnormal interpretation was significantly lower after than it was before implementation (5.0% vs 6.3%; p < .001). Cancer detection rate and PPV1 (PPV based on positive findings at screening examination) were not significantly different before and after implementation (p > .05). CONCLUSION. Implementation of the immediate-read screening mammography program reduced prior racial and ethnic disparities in same-day diagnostic imaging after abnormal screening mammograms. CLINICAL IMPACT. An immediate-read screening program provides a new paradigm for improved screening mammography workflow that allows more rapid diagnostic workup with reduced disparities in care.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , COVID-19/prevenção & controle , Diagnóstico Tardio/prevenção & controle , Disparidades em Assistência à Saúde/estatística & dados numéricos , Interpretação de Imagem Assistida por Computador/métodos , Mamografia/métodos , Grupos Raciais/estatística & dados numéricos , Adulto , Mama/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Pandemias , Estudos Retrospectivos , SARS-CoV-2 , TempoRESUMO
PURPOSE: Mammography screening encounters may represent ideal opportunities to identify high-risk women for risk-based screening. During mammography appointments, radiology practices evaluate breast density and ascertain known breast cancer risk factors. Our purpose was to evaluate the potential for mammographic screening encounters to identify high-risk women by estimating the (1) proportion of high-risk women who report that they have undergone mammographic screening and the (2) proportion of high-risk women who receive recommendations for breast MRI screening. METHODS: Women ages 30-85 without breast cancer histories were included from the 2015 National Health Interview Survey, a nationally representative cross-sectional household survey (response rate 80%). Breast Cancer Risk Assessment Tool was used to determine high-risk (lifetime risk>20%). Among high-risk women, primary outcome was proportion reporting mammography screening, secondary outcome was receipt of a breast MRI recommendation after recent mammogram, accounting for complex survey design. RESULTS: 14,958 women were included. 1.0% were high-risk of whom: 91.9% ever had a mammogram, 68.0% had a mammogram within the last year, 81.5% had a mammogram within the last 2 years. 6.4% were recommended to undergo breast MRI. Among high-risk women, women with dense breast tissue were more likely (OR 496.0, 95%CI 52.6,4674.0) and older women were less likely (OR 0.91, 95%CI 0.84,0.99) to receive recommendations for breast MRI. CONCLUSIONS: Among high-risk women, 92% reported undergoing at least one mammogram in their lives. 94% did not receive recommendations for breast MRI screening and 32% did not have a mammogram within the last year. To identify high-risk women, breast imaging centers should consider determining lifetime breast cancer risk during mammography screening visits.
Assuntos
Neoplasias da Mama , Mamografia , Adulto , Idoso , Idoso de 80 Anos ou mais , Densidade da Mama , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/epidemiologia , Estudos Transversais , Detecção Precoce de Câncer , Feminino , Humanos , Programas de Rastreamento , Pessoa de Meia-IdadeRESUMO
OBJECTIVE. The purpose of this study is to determine the impact of shear-wave elastography (SWE) image quality parameters on the diagnostic performance of elasticity measurements in classifying breast lesions. MATERIALS AND METHODS. This retrospective study included 281 breast lesions that underwent SWE and ultrasound-guided biopsy performed between October 1, 2017, and August 31, 2018. Three readers who were blinded to pathologic outcomes independently scored the image quality of each SWE image (with low quality denoted by a score of 0 and high quality indicated by a score of 1) on the basis of five parameters: B-mode visualization of the lesion on a dual-panel display, SWE red pattern (denoting high stiffness) in the near field of the FOV, appearance of the surrounding tissue, FOV placement, and ROI placement for the maximum (Emax), minimum (Emin), mean (Emean), and SD (ESD) of Young modulus elasticity measurements. Using ROC analysis, we compared the performance of Emax, Emean, and ESD in diagnosing malignancy on low- and high-quality images on the basis of consensus (i.e., majority) scores for each individual quality parameter as well as two models combining a few of the quality parameters. RESULTS. Three quality parameters (B-mode visualization of the lesion, presence of a near-field red pattern, and the appearance of the surrounding tissue) showed moderate-to-substantial interobserver agreement. SWE images were considered high quality (n = 167) if both B-mode visualization and near-field red pattern received a consensus score of 1, and they were considered low quality (n = 114) if either parameter received a consensus score of 0. High-quality images had a statistically higher AUC value than low-quality images when Emax (p < .001), Emean (p = .002), and ESD (p < .001) were used as classifiers of malignancy. CONCLUSION. Quality parameters can support radiologists who are performing and interpreting breast SWE images. These quality parameters have the potential to improve the accuracy of SWE in differentiating malignant from benign breast lesions.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Técnicas de Imagem por Elasticidade/métodos , Ultrassonografia Mamária/métodos , Adulto , Idoso , Mama/diagnóstico por imagem , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
BACKGROUND. Lumbar spine MRI is associated with a high prevalence of interpretive errors by radiologists. Treating physicians can obtain symptom information, correlate symptoms with MRI findings, and distinguish presumptive pain generators from incidental abnormalities. OBJECTIVE. The purpose of this study was to capture symptom information using a patient questionnaire, review lumbar spine MRI examinations with and without symptom information, diagnose pain generators, and compare MRI diagnoses with clinical reference diagnoses. METHODS. In this prospective study, 120 participants (70 men and 50 women; median age, 64 years; interquartile range, 49.5-74 years) were recruited from patients referred for lumbar spine injections between February and June 2019. Participants completed electronic questionnaires regarding their symptoms before receiving the injections. For three research arms, six radiologists diagnosed pain generators in MRI studies reviewed with symptom information from questionnaires, MRI studies reviewed without symptom information, and MRI reports. Interreading agreement was analyzed. Blinded to the questionnaire results, the radiologists who performed injections obtained patient histories, correlated symptoms with MRI findings, and diagnosed presumptive pain generators. These diagnoses served as clinical reference standards. Pain generators were categorized by type, level, and side and were compared using kappa statistics. Diagnostic certainty was recorded using numeric values (0-100) and was compared using Wilcoxon rank-sum test RESULTS. When compared with the reference standard, agreement for the type, level, and side of pain generator was almost perfect in MRI examinations reviewed with symptom information (κ = 0.82-0.90), fair to moderate in MRI examinations reviewed without symptom information (κ = 0.28-0.51) (all p < .001), and fair to moderate in MRI reports (κ = 0.27-0.45) (all p < .001). Interreading agreement was almost perfect when MRI examinations were reviewed with symptom information (κ = 0.82-0.90) but was only moderate without symptom information (κ = 0.42-0.56) (all p < .001). Diagnostic certainty levels were highest for radiologists performing injections (mean [± SD], 90.0 ± 9.9) and were significantly higher for MRI review with symptom information versus without symptom information (means for reading 1, 84.6 ± 13.1 vs 62.9 ± 20.7; p < .001). CONCLUSION. In lumbar spine MRI, presumptive pain generators diagnosed using symptom information from electronic questionnaires showed almost perfect agreement with pain generators diagnosed using symptom information from direct patient interviews. CLINICAL IMPACT. Patient-reported symptom information from a brief questionnaire can be correlated with MRI findings to distinguish presumptive pain generators from incidental abnormalities.
Assuntos
Dor Lombar/diagnóstico por imagem , Vértebras Lombares/diagnóstico por imagem , Imageamento por Ressonância Magnética , Questionário de Saúde do Paciente , Idoso , Feminino , Humanos , Dor Lombar/etiologia , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
BACKGROUND AND PURPOSE: Lumbar spine MRI can help guide the choice of corticosteroid injection in pain management. We investigated whether patient-reported symptom information from a questionnaire could improve agreement in the choice of type, level, and side of injection. MATERIALS AND METHODS: In this prospective observational study, 120 patients (median age 64, 70 men) were recruited from patients referred for pain management. After informed consent, they completed electronic questionnaires that obtained symptom information for later use during MRI reviews. In 3 research arms, 6 radiologists chose injections that would ideally deliver corticosteroid to the presumed sources of pain in (1) MRI studies reviewed with symptom information from questionnaires, (2) MRI studies reviewed without symptom information, and (3) MRI reports. Blinded to questionnaire results, radiologists providing clinical care and interviewing patients chose ideal therapeutic injections to establish reference standards. Injections were categorized by type, level, and side and compared using percent agreement and kappa statistics. Interreading agreement was analyzed. RESULTS: Compared to the reference standard, kappa agreements for injection types, levels, and sides were almost perfect when MRIs were reviewed knowing symptoms (0.85-0.93), fair without symptoms (0.23-0.35) (all P < .001) and fair in MRI reports (0.24-0.36) (all P < .001). Interreading kappa agreements were almost perfect knowing symptoms (0.82-0.90), but only moderate without symptoms (0.42-0.49) (all P < .001). CONCLUSIONS: Radiologists reviewing lumbar spine MRI converged on the type, level, and side of ideal therapeutic injection whether they obtained symptom information from direct patient interview or electronic questionnaire. Observer agreement was significantly lower without symptom information.
Assuntos
Vértebras Lombares , Manejo da Dor , Humanos , Vértebras Lombares/diagnóstico por imagem , Região Lombossacral , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Variações Dependentes do Observador , Estudos ProspectivosRESUMO
OBJECTIVE. The purpose of this study was to evaluate the frequency and cancer yield of BI-RADS category 3 lesions in baseline versus nonbaseline (those with at least one prior) MRI screening examinations. MATERIALS AND METHODS. Consecutive MRI screening examinations performed from 2011 through 2015 were reviewed. Pearson and Wilcoxon tests were used to examine differences in age, breast density, screening indication, background parenchymal enhancement, and cancer yield between baseline and nonbaseline MRI BI-RADS category 3 assessments. Multivariate logistic regression models based on generalized estimating equations were used to assess the odds of receiving a BI-RADS 3 assessment as a function of the variables. RESULTS. Of 6672 MRI screening examinations of 3214 patients, 202 examinations (3%) were assessed BI-RADS category 3. Among baseline examinations, 8% (82/983) were assessed BI-RADS 3, compared with 2% (120/5689) of nonbaseline examinations (p < 0.001). Among the total BI-RADS 3 examinations, 6% (13/202) yielded malignancy of the lesion that had been assessed BI-RADS 3; 12 of 13 cancers were stage 0 or I at diagnosis. The cancer yield of BI-RADS 3 at baseline examinations was 2% (2/82), compared with 9% (11/120) for nonbaseline examinations (p = 0.056). Ten of 13 examinations were upgraded at or before 6-month follow-up MRI. CONCLUSION. Baseline screening breast MRI examinations are associated with a significantly higher rate of BI-RADS category 3 assessments than are nonbaseline examinations. Most cancers diagnosed at follow-up of BI-RADS 3 lesions are in an early stage and are diagnosed at or before the 6-month follow-up examination. When used judiciously, short-interval follow-up MRI is an appropriate method for identifying early-stage breast cancer while avoiding unnecessary biopsies with benign findings.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Adulto , Densidade da Mama , Neoplasias da Mama/patologia , Meios de Contraste , Diagnóstico Diferencial , Detecção Precoce de Câncer , Feminino , Humanos , Interpretação de Imagem Assistida por Computador , Programas de Rastreamento , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
BACKGROUND: Postmenopausal obese women demonstrate an elevated breast cancer risk and experience increased breast cancer morbidity and mortality compared with women with a normal body mass index (BMI). However, to the authors' knowledge, prior studies have yielded inconclusive results regarding the effects of obesity on mammography screening adherence. Using national cross-sectional survey data, the objective of the current study was to assess the current association between increasing BMI and use of mammography screening. METHODS: Cross-sectional survey data from the 2016 Behavioral Risk Factor Surveillance System, a state-based national telephone survey of noninstitutionalized adults in the United States, was used to identify the association between mammography screening use and increasing incremental BMI categories, including normal (18.5-24.9 kg/m2 ), overweight (25-29.9 kg/m2 ), obese class I (30-34.9 kg/m2 ), obese class II (35-39.9 kg/m2 ), and obese class III (>40 kg/m2 ), with adjustments for potential confounders. A multivariable logistic regression model was used to evaluate the effect of each BMI category on self-reported mammography use, using unadjusted and adjusted odds ratios. Effect modification by race/ethnicity was determined by testing interaction terms using Wald tests. RESULTS: Of 116,343 survey respondents, 33.5% (38,984 respondents) had a normal BMI, 32.6% (37,969 respondents) were overweight, 19.3% (22,416 respondents) were classified as obese class I, 8.4% (9791 respondents) were classified as obese class II, and 6.2% (7183 respondents) were classified as obese class III. There was no statistically significant difference (P < .05) observed with regard to mammography use between women with a normal BMI and obese women from each obese class (classes I-III) when compared individually. There also was no evidence of effect modification by race (P = .53). CONCLUSIONS: In contrast to prior reports, the results of the current study demonstrated no association between obesity and adherence to screening mammography. These findings may relate to the increasing social acceptance of obesity among women from all racial/ethnic groups and the removal of weight-related facility-level barriers over time.
Assuntos
Sistema de Vigilância de Fator de Risco Comportamental , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/etiologia , Obesidade/epidemiologia , Idoso , Estudos Transversais , Detecção Precoce de Câncer , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Background Screening breast MRI is recommended for women with BRCA mutation or a history of chest radiation, but guidelines are equivocal for MRI screening of women with a personal history of breast cancer or high-risk lesion. Purpose To evaluate screening breast MRI performance across women with different elevated breast cancer risk indications. Materials and Methods All screening breast MRI examinations performed between 2011 and 2014 underwent retrospective medical record review. Indications for screening were as follows: BRCA mutation carrier or history of chest radiation (BRCA/RT group), family history of breast cancer (FH group), personal history of breast cancer (PH group), and history of high-risk lesion (HRL group). Screening performance metrics were calculated and compared among indications by using logistic regression adjusted for age, available prior MRI, mammographic density, examination year, and multiple risk factors. Results There were 5170 screening examinations in 2637 women (mean age, 52 years; range, 23-86 years); 67 breast cancers were detected. The cancer detection rate (CDR) was highest in the BRCA/RT group (26 per 1000 examinations; 95% confidence interval [CI]: 16, 43 per 1000 examinations), intermediate for those in the PH and HRL groups (12 per 1000 examinations [95% CI: 9, 17 per 1000 examinations] and 15 per 1000 examinations [95% CI: 7, 32 per 1000 examinations], respectively), and lowest for those in the FH group (8 per 1000 examinations; 95% CI: 4, 14 per 1000 examinations). No difference in CDR was evident for the PH or HRL group compared with the BRCA/RT group (P = .14 and .18, respectively). The CDR was lower for the FH group compared with the BRCA/RT group (P = .02). No difference was evident in positive predictive value for biopsies performed (PPV3) for the BRCA/RT group (41%; 95% CI: 26%, 56%) compared with the PH (41%; 95% CI: 31%, 52%; P = .63) or HRL (36%, 95% CI: 17%, 60%; P = .37) groups. PPV3 was lower for the FH group (14%; 95% CI: 8%, 25%; P = .048). Conclusion Screening breast MRI should be considered for women with a personal history of breast cancer or high-risk lesion. Worse screening MRI performance in patients with a family history of breast cancer suggests that better risk assessment strategies may benefit these women. © RSNA, 2019.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Imageamento por Ressonância Magnética/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Mama/diagnóstico por imagem , Feminino , Humanos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Fatores de Risco , Adulto JovemRESUMO
OBJECTIVE: The purpose of this study is to evaluate the effect of background parenchymal enhancement (BPE) on breast cancer risk across different high-risk patient populations undergoing screening breast MRI. MATERIALS AND METHODS: Consecutive screening breast MRI examinations performed between 2011 and 2014 were reviewed. Multivariate logistic regression using generalized estimating equations was used to assess the association of the following variables with cancer risk: age, qualitative BPE prospective clinical assessment (minimal or mild vs moderate or marked), mammographic breast density (dense vs not dense), and screening indication (prioritized in the following order: BRCA carrier or history of thoracic radiation, breast cancer personal history, high-risk lesion, and breast cancer family history). Cancer diagnosis was defined as a tissue diagnosis of invasive or in situ carcinoma within 12 months of the screening MRI. RESULTS: The study cohort included 4686 screening MRI examinations performed in 2446 women, grouped by BPE as minimal or mild (3975/4686; 85%) versus moderate or marked (711/4686; 15%) and by screening indication as BRCA carrier or history of thoracic radiation (548/4686; 12%), breast cancer personal history (2541/4686; 54%), high-risk lesion (362/4686; 8%), and breast cancer family history (1235/4686; 26%). After adjustment for confounding variables, only BPE and screening indication were independent predictors of cancer diagnosis (p = 0.02 and p < 0.01, respectively). The odds ratio for developing cancer in the moderate or marked BPE group compared with the minimal or mild group was 2.1 (95% CI, 1.1-4.0), after adjusting for age, breast density, and screening indication. CONCLUSION: Increased BPE level is an independent predictor of breast cancer in women undergoing screening MRI for different high-risk indications.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Detecção Precoce de Câncer , Aumento da Imagem/métodos , Imageamento por Ressonância Magnética/métodos , Programas de Rastreamento , Adulto , Fatores Etários , Idoso , Densidade da Mama , Neoplasias da Mama/patologia , Carcinoma in Situ/diagnóstico por imagem , Carcinoma in Situ/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Invasividade Neoplásica/diagnóstico por imagem , Invasividade Neoplásica/patologia , Estudos Retrospectivos , Medição de Risco , Fatores de RiscoRESUMO
OBJECTIVE: The objective of our study was to test for the possibility that published malignancy risks for side-branch intraductal papillary mucinous neoplasms (IPMNs) are overestimates, likely due to verification bias. MATERIALS AND METHODS: We tested for possible verification bias using simulation modeling techniques. First, in age-defined hypothetical cohorts of 10 million persons, we projected the frequency of pancreatic ductal adenocarcinoma (PDAC) arising from side-branch IPMNs over 5 years using published estimates of their prevalence (4.4%) and rate of malignant transformation (1.9%). Second, we projected the total number of PDAC cases in corresponding cohorts over the same time horizon using national cancer registry data. For each cohort, we determined whether the percentage of all PDAC cases that arose from side-branch IPMNs (i.e., side-branch IPMN-associated PDAC cases) was clinically plausible using an upper limit of 10% to define plausibility, as estimated from the literature. Model assumptions and parameter uncertainty were evaluated in sensitivity analysis. RESULTS: Across all cohorts, percentages of side-branch IPMN-associated PDACs greatly exceeded 10%. In the base case (mean age = 55.7 years), 80% of PDAC cases arose from side-branch IPMNs (7877/9786). In the oldest cohort evaluated (mean age = 75 years), this estimate was 76% (14,227/18,714). In a secondary analysis, we found that if an upper limit threshold of 10% for side-branch IPMN-associated PDAC was imposed, the model-predicted rate of malignancy for side-branch IPMNs would be less than 0.24% over a 5-year time horizon, substantially lower than most literature-based estimates. CONCLUSION: Our results suggest that reported malignancy risks associated with side-branch IPMNs are likely to be overestimates and imply the presence of verification bias.
Assuntos
Adenocarcinoma Papilar/patologia , Carcinoma Ductal Pancreático/patologia , Neoplasias Pancreáticas/patologia , Adenocarcinoma Papilar/epidemiologia , Viés , Carcinoma Ductal Pancreático/epidemiologia , Simulação por Computador , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/epidemiologia , PrevalênciaRESUMO
OBJECTIVE: To determine the incidence, timing, and long-term outcomes of unilateral axillary lymphadenopathy ipsilateral to vaccine site (UIAL) on screening mammography after COVID-19 vaccination. METHODS: This retrospective, multisite study included consecutive patients undergoing screening mammography February 8, 2021, to January 31, 2022, with at least 1 year of follow-up. UIAL was typically considered benign (BI-RADS 1 or 2) in the setting of recent (≤6 weeks) vaccination or BI-RADS 0 (ultrasound recommended) when accompanied by a breast finding or identified >6 weeks postvaccination. Vaccination status and manufacturer were obtained from regional registries. Lymphadenopathy rates in vaccinated patients with and without UIAL were compared using Pearson's χ2 test. RESULTS: There were 44,473 female patients (mean age 60.4 ± 11.4 years) who underwent screening mammography at five sites, and 40,029 (90.0%) received at least one vaccine dose. Ninety-four (0.2%) presented with UIAL, 1 to 191 days postvaccination (median 13.5 [interquartile range: 5.0-31.0]). Incidence declined from 2.1% to 0.9% to ≤0.5% after 1, 2, and 3 weeks and persisted up to 36 weeks (P < .001). UIAL did not vary across manufacturer (P = .15). Of 94, 77 (81.9%) were BI-RADS 1 or 2 at screening. None were diagnosed with malignancy at 1-year follow-up. Seventeen (18.1%) were BI-RADS 0 at screening. At diagnostic workup, 13 (76.5%) were BI-RADS 1 or 2, 2 (11.8%) were BI-RADS 3, and 2 (11.8%) were BI-RADS 4. Both BI-RADS 4 patients had malignant status and ipsilateral breast malignancies. Of BI-RADS 3 patients, at follow-up, one was biopsied yielding benign etiology, and one was downgraded to BI-RADS 2. DISCUSSION: Isolated UIAL on screening mammography performed within 6 months of COVID-19 vaccination can be safely assessed as benign.
RESUMO
OBJECTIVE: Patients who miss screening mammogram appointments without notifying the health care system (no-show) risk care delays. We investigate sociodemographic characteristics of patients who experience screening mammogram no-shows at a community health center and whether and when the missed examinations are completed. METHODS: We included patients with screening mammogram appointments at a community health center between January 1, 2021, and December 31, 2021. Language, race, ethnicity, insurance type, residential ZIP code tabulation area (ZCTA) poverty, appointment outcome (no-show, same-day cancelation, completed), and dates of completed screening mammograms after no-show appointments with ≥1-year follow-up were collected. Multivariable analyses were used to assess associations between patient characteristics and appointment outcomes. RESULTS: Of 6,159 patients, 12.1% (743 of 6,159) experienced no-shows. The no-show group differed from the completed group by language, race and ethnicity, insurance type, and poverty level (all P < .05). Patients with no-shows more often had: primary language other than English (32.0% [238 of 743] versus 26.7% [1,265 of 4,741]), race and ethnicity other than White non-Hispanic (42.3% [314 of 743] versus 33.6% [1,595 of 4,742]), Medicaid or means-tested insurance (62.0% [461 of 743] versus 34.4% [1,629 of 4,742]), and residential ZCTAs with ≥20% poverty (19.5% [145 of 743] versus 14.1% [670 of 4,742]). Independent predictors of no-shows were Black non-Hispanic race and ethnicity (adjusted odds ratio [aOR], 1.52; 95% confidence interval [CI], 1.12-2.07; P = .007), Medicaid or other means-tested insurance (aOR, 2.75; 95% CI, 2.29-3.30; P < .001), and ZCTAs with ≥20% poverty (aOR, 1.76; 95% CI, 1.14-2.72; P = .011). At 1-year follow-up, 40.6% (302 of 743) of patients with no-shows had not completed screening mammogram. DISCUSSION: Screening mammogram no-shows is a health equity issue in which socio-economically disadvantaged and racially and ethnically minoritized patients are more likely to experience missed appointments and continued delays in screening mammogram completion.
RESUMO
BACKGROUND AND PURPOSE: Mass effect and vasogenic edema are critical findings on CT of the head. This study compared the accuracy of an artificial intelligence model (Annalise Enterprise CTB) with consensus neuroradiologists' interpretations in detecting mass effect and vasogenic edema. MATERIALS AND METHODS: A retrospective stand-alone performance assessment was conducted on data sets of noncontrast CT head cases acquired between 2016 and 2022 for each finding. The cases were obtained from patients 18 years of age or older from 5 hospitals in the United States. The positive cases were selected consecutively on the basis of the original clinical reports using natural language processing and manual confirmation. The negative cases were selected by taking the next negative case acquired from the same CT scanner after positive cases. Each case was interpreted independently by up-to-three neuroradiologists to establish consensus interpretations. Each case was then interpreted by the artificial intelligence model for the presence of the relevant finding. The neuroradiologists were provided with the entire CT study. The artificial intelligence model separately received thin (≤1.5 mm) and/or thick (>1.5 and ≤5 mm) axial series. RESULTS: The 2 cohorts included 818 cases for mass effect and 310 cases for vasogenic edema. The artificial intelligence model identified mass effect with a sensitivity of 96.6% (95% CI, 94.9%-98.2%) and a specificity of 89.8% (95% CI, 84.7%-94.2%) for the thin series, and 95.3% (95% CI, 93.5%-96.8%) and 93.1% (95% CI, 89.1%-96.6%) for the thick series. It identified vasogenic edema with a sensitivity of 90.2% (95% CI, 82.0%-96.7%) and a specificity of 93.5% (95% CI, 88.9%-97.2%) for the thin series, and 90.0% (95% CI, 84.0%-96.0%) and 95.5% (95% CI, 92.5%-98.0%) for the thick series. The corresponding areas under the curve were at least 0.980. CONCLUSIONS: The assessed artificial intelligence model accurately identified mass effect and vasogenic edema in this CT data set. It could assist the clinical workflow by prioritizing interpretation of cases with abnormal findings, possibly benefiting patients through earlier identification and subsequent treatment.
RESUMO
PURPOSE: The aim of this study was to investigate disparities in time between breast biopsy recommendation and completion and the impact of a same-day biopsy (SDB) program for patients with serious mental illness (SMI), with a focus on more vulnerable individuals with public payer insurance. METHODS: In August 2017, the authors' academic breast imaging center started routinely offering needle biopsies on the day of recommendation. Primary outcomes were the proportion of biopsies performed as SDBs and days from biopsy recommendation to completion over a 2.5-year pre- versus postintervention period, comparing all patients with SMI versus those without, and public payer-insured patients <65 years of age with SMI (SMI-PP) versus without SMI (non-SMI-PP). Multivariable proportional odds and logistic regression models were fit to assess association of SMI status, age, race/ethnicity, language, and insurance with days to biopsy and SDB within each period. RESULTS: There were 2,026 biopsies preintervention and 2,361 biopsies postintervention. Preintervention, 8.43% of patients with SMI (7 of 83) underwent SDB compared with 15.59% of those without SMI (303 of 1,943) (P = .076), and 2.7% of the SMI-PP subgroup (1 of 37) underwent SDB compared with 15.88% of the non-SMI-PP subgroup (47 of 296) (P = .031). Adjusted for age, race/ethnicity, and language, disparities persisted in odds for undergoing SDB (adjusted odds ratio, 0.13; 95% confidence interval, 0.02-0.92; P = .04) and having longer days to biopsy (adjusted odds ratio, 2.35; 95% confidence interval, 1.26-4.37; P = .01) for the SMI-PP subgroup compared with the non-SMI-PP subgroup in the preintervention period. There was no evidence of these disparities postintervention for the SMI-PP subgroup. SDB proportion increased from 15.3% (310 of 2,026) to 36.09% (852 of 2,361) (P < .001) across all patients. CONCLUSIONS: A same-day breast biopsy program mitigates disparities in time to biopsy for patients with SMI and helps improve breast cancer care equity for this vulnerable population.
Assuntos
Neoplasias da Mama , Transtornos Mentais , Biópsia por Agulha , Mama/diagnóstico por imagem , Mama/patologia , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/patologia , Feminino , Humanos , Transtornos Mentais/epidemiologia , Razão de ChancesRESUMO
OBJECTIVE: Legislation in 38 states requires patient notification of dense mammographic breast tissue because increased density is a marker of breast cancer risk and can limit mammographic sensitivity. Because radiologist density assessments vary widely, our objective was to implement and measure the impact of a deep learning (DL) model on mammographic breast density assessments in clinical practice. METHODS: This institutional review board-approved prospective study identified consecutive screening mammograms performed across three clinical sites over two periods: 2017 period (January 1, 2017, through September 30, 2017) and 2019 period (January 1, 2019, through September 30, 2019). The DL model was implemented at sites A (academic practice) and B (community practice) in 2018 for all screening mammograms. Site C (community practice) was never exposed to the DL model. Prospective densities were evaluated, and multivariable logistic regression models evaluated the odds of a dense mammogram classification as a function of time and site. RESULTS: We identified 85,124 consecutive screening mammograms across the three sites. Across time intervals, odds of a dense classification decreased at sites exposed to the DL model, site A (adjusted odds ratio [aOR], 0.93; 95% confidence interval [CI], 0.86-0.99; P = .024) and site B (aOR, 0.81 [95% CI, 0.70-0.93]; P = .003), and odds increased at the site unexposed to the model (site C) (aOR, 1.13 [95% CI, 1.01-1.27]; P = .033). DISCUSSION: A DL model reduces the odds of screening mammograms categorized as dense. Accurate density assessments could help health care systems more appropriately use limited supplemental screening resources and help better inform traditional clinical risk models.
Assuntos
Neoplasias da Mama , Aprendizado Profundo , Densidade da Mama , Neoplasias da Mama/diagnóstico por imagem , Feminino , Humanos , Modelos Logísticos , Mamografia , Estudos ProspectivosRESUMO
OBJECTIVE: To determine the long-term cardiovascular disease risk of astronauts with spaceflight exposure compared with a well-matched cohort. METHODS: National Aeronautics and Space Administration (NASA) astronauts are selected into their profession based upon education, unique skills, and health and are exposed to cardiovascular disease risk factors during spaceflight. The Cooper Center Longitudinal Study (CCLS) is a generally healthy cohort from a preventive medicine clinic in Dallas, Texas. Using a matched cohort design, astronauts who were selected beginning April 1, 1959, (and each subsequent selection class through 2009) and exposed to spaceflight were matched to CCLS participants who met astronaut selection criteria; 1514 CCLS participants matched to 303 astronauts in a 5-to-1 ratio on sex, date of birth, and age. The outcome of cardiovascular mortality through December 31, 2016, was determined by death certificate or National Death Index. RESULTS: There were 11 deaths caused by cardiovascular disease (CVD) among astronauts and 46 among CCLS participants. There was no evidence of increased mortality risk in astronauts (hazard ratio [HR]=1.10; 95% confidence interval [CI], 0.50 to 2.45) with adjustment for baseline cardiovascular covariates. However, the secondary outcome of CVD events showed an increased adjusted risk in astronauts (HR=2.41; 95% CI, 1.26 to 4.63). CONCLUSION: No increased risk of CVD mortality was observed in astronauts with spaceflight exposure compared with a well-matched cohort, but there was evidence of increased total CVD events. Given that the duration of spaceflight will increase, particularly on missions to Mars, continued surveillance and mitigation of CVD risk is needed to ensure the safety of those who venture into space.
Assuntos
Astronautas , Doenças Cardiovasculares , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Fatores de Risco de Doenças Cardíacas , Humanos , Estudos Longitudinais , Fatores de Risco , Estados Unidos/epidemiologia , United States National Aeronautics and Space AdministrationRESUMO
INTRODUCTION: Patients with pyogenic spinal Infection (PSI) are often not diagnosed at their initial presentation, and diagnostic delay is associated with increased morbidity and medical-legal risk. We derived a decision tool to estimate the risk of spinal infection and inform magnetic resonance imaging (MRI) decisions. METHODS: We conducted a two-part prospective observational cohort study that collected variables from spine pain patients over a six-year derivation phase. We fit a multivariable regression model with logistic coefficients rounded to the nearest integer and used them for variable weighting in the final risk score. This score, SIRCH (spine infection risk calculation heuristic), uses four clinical variables to predict PSI. We calculated the statistical performance, MRI utilization, and model fit in the derivation phase. In the second phase we used the same protocol but enrolled only confirmed cases of spinal infection to assess the sensitivity of our prediction tool. RESULTS: In the derivation phase, we evaluated 134 non-PSI and 40 PSI patients; median age in years was 55.5 (interquartile range [IQR] 38-70 and 51.5 (42-59), respectively. We identified four predictors for our risk score: historical risk factors; fever; progressive neurological deficit; and C-reactive protein (CRP) ≥ 50 milligrams per liter (mg/L). At a threshold SIRCH score of ≥ 3, the predictive model's sensitivity, specificity, and positive predictive value were, respectively, as follows: 100% (95% confidence interval [CI], 100-100%); 56% (95% CI, 48-64%), and 40% (95% CI, 36-46%). The area under the receiver operator curve was 0.877 (95% CI, 0.829-0.925). The SIRCH score at a threshold of ≥ 3 would prompt significantly fewer MRIs compared to using an elevated CRP (only 99/174 MRIs compared to 144/174 MRIs, P <0.001). In the second phase (49 patient disease-only cohort), the sensitivities of the SIRCH score and CRP use (laboratory standard cut-off 3.5 mg/L) were 92% (95% CI, 84-98%), and 98% (95% CI, 94-100%), respectively. CONCLUSION: The SIRCH score provides a sensitive estimate of spinal infection risk and prompts fewer MRIs than elevated CRP (cut-off 3.5 mg/L) or clinician suspicion.